Aide memoire
September 2026

Stockholm, 21 September 2026. Sobi (NASDAQ: SOBI) has compiled the following items and prior disclosures for consideration to assist in the financial modelling of the Company's Q3 2026 results.
Sobi Q2 2026 communications can be found on sobi.com/investors.

Business Items

Overall Q2 2026 revenue performance and general comments

Total revenue for Q2 2026 was SEK 7,842 M and increased by 29 per cent at CER. Strong growth from Altuvoct, Doptelet, Gamifant and Kineret was partially offset by lower sales of Elocta.

During Q3 2026 Sobi announced it has entered a strategic partnership with Innate Pharma to license lacutamab in T-cell lymphoma. Under the terms of the agreement, Sobi will pay Innate Pharma USD 75 million, payable on closing. The deal closure announcement was published on 16th September 2026. Additionally, Guido Oelkers announced his intention to step down as CEO of Sobi at the beginning of 2027.

Please note the following previously communicated product performances (growth at CER):

Haematology

- **Elocta and Altuvoct**: Altuvoct sales were SEK 1,554 M (627) in the Q2 2026, following strong launches and initial sales in 30 countries led by Germany, France, the UK, Spain and Italy. Elocta sales were SEK 702 M (991) in Q2 2026 and decreased by 27 per cent at CER. Sales of Elocta were as expected impacted by switch of patients to Altuvoct in launched markets. The combined haemophilia A sales increased 41 per cent at CER in Q2 2026.
- **Alprolix:** sales were SEK 567 M in Q2 2026 and increased by 1 per cent at CER.
- **Doptelet:** revenue was SEK 1,628 M in Q2 2026 and increased by 36 per cent at CER. The strong performance was driven by increased uptake across markets.
- **Aspaveli/Empaveli:** sales were SEK 354 M in Q2 2026 and increased by 18 per cent at CER mainly reflecting new nephrology patients and partially offset by phasing in the international region.
- **Vonjo:** sales were SEK 317 M in Q2 2026 and increased by 8 per cent at CER. The growth was driven by demand and positive gross-to-net effects in the US.
- **Zynlonta:** sales were SEK 36 M in Q2 2026.

Immunology

- **Kineret:** sales were SEK 861 M in Q2 2026 and increased by 19 per cent at CER, driven by increased demand across regions.
- **Gamifant**: sales were SEK 794 M in Q2 2026 and increased by 29 per cent at CER, driven by new patients treated for MAS in Still's disease in the US and an increase in the total number of patients on treatment.
- **Beyfortus:** Royalty earned from Sanofi's sales of Beyfortus in the US was SEK 56 M in Q2 2026.

Specialty care

Specialty Care revenue was SEK 405 M in Q2 2026 and increased by 29 per cent at CER. Tryngolza sales were SEK 47 M in Q2 2026 driven by the launch in FCS.

Financials

OPEX

- Selling and administrative expenses were SEK 3,339 M (2,872) in Q2 2026 (Q2 2025), including amortisation of SEK 1,217 M (853). IAC amounted to SEK 445 M (137). Excluding these costs and amortisation and impairment, the selling and administrative expenses increased by 15 per cent at CER.
- R&D expenses were SEK 1,143 M (851) in Q2 2026 (Q2 2025).

Estimated currency impact

- Based on the evolution of foreign currencies, the preliminary estimate is a neutral impact on Sobi's Q3 2026 revenue of between -1% and 1% compared to constant exchange rates.

Tax rate

- Income tax was SEK -315 M (-160) in the quarter, corresponding to an effective tax rate (ETR) of 22.3 per cent (20.1) in Q2 2026. The higher effective tax rate was mainly driven by an increased impact from higher tax jurisdictions.

Number of Shares

- Average number of ordinary shares after dilution (excluding treasury shares) was 350,056,085 in Q2 2026.

Outlook 2026

- Revenue is anticipated to grow by a mid-to high-teens percentage at CER.
- The adjusted EBITA margin is anticipated to be in the mid-to high-30s percentage of revenue.

Forward-looking statements

This document contains certain forward-looking statements with respect to certain of the Company's current expectations and projections about future events. These statements, which sometimes use words such as "intend," "proposed," "plan," "expect," and words of similar meaning, reflect management's beliefs and expectations and involve a number of risks, uncertainties and assumptions that could cause actual results and performance to differ materially from any expected future results or performance expressed or implied by the forward-looking statement. Statements contained in this presentation regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. The information contained in this presentation is subject to change without notice and, except as required by applicable law, the Company does not assume any responsibility or obligation to update publicly or review any of the forward-looking statements contained in it. You should not place undue reliance on forward-looking statements, which speak only as at the date of this presentation.

Sobi®

Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. Sobi has approximately 2,000 employees across Europe, North America, the Middle East, Asia and Australia. In 2025, revenue amounted to SEK 28 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and LinkedIn.

Contacts

For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here.

Gerard Tobin
Head of Investor Relations